Cours suspendu

Autres langues Aptose Biosciences Inc. OTC Markets

Actions

APTO

CA03835T4081

Produits pharmaceutiques

Temps Différé OTC Markets Autres places de cotation 17:53:32 02/07/2026			Varia. 5j.	Varia. 1 janv.
1,690 ^USD	+0,90%		0,00%	+14,19%

02/07	Hanmi Pharmaceutical finalise l'acquisition d'Aptose Biosciences	MT
30/06	Hanmi Pharm. Co., Ltd. (KOSE:A128940) a finalisé l'acquisition de la participation résiduelle de 80,07 % dans Aptose Biosciences Inc. (TSX:APS).	CI

Autres langues

02/07	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences
01/07	Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
30/06	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..
15/06	Aptose Biosciences Inc. Presents Safety, Response and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML
15/06	Aptose Biosciences Updated Tuscany Trial Data Reported in Oral Presentation at EHA 2026
15/06	Aptose Biosciences : Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
15/06	Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
29/05	Aptose Biosciences Says Acquisition by Hanmi Delayed Until June
29/05	Aptose Biosciences says closing of arrangement with Hanmi Pharmaceutical further delayed
29/05	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
13/05	Aptose Biosciences: Q1 Earnings Snapshot
13/05	Aptose Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
13/05	Aptose Biosciences : Reports First Quarter 2026 Results
13/05	Aptose Reports First Quarter 2026 Results
30/04	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
01/04	Aptose Biosciences: Q4 Earnings Snapshot
31/03	Aptose Shareholders Approve Acquisition By Hanmi Pharmaceutical in "Go Private" Transaction
31/03	Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
31/03	Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
31/03	Aptose Biosciences Inc. Auditor Raises 'Going Concern' Doubt
23/03	Leading independent proxy advisory firm Glass Lewis endorses Aptose plan of arrangement
23/03	Aptose Biosciences Brief: Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement With Hanmi Pharmaceutical
23/03	Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
20/03	Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote FOR Proposed Plan of Arrangement with Hanmi Pharmaceutical
19/03	Leading independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote "for" proposed plan of arrangement with Hanmi Pharmaceutical